Emyria Ltd’s Michael Winlo tells Andrew Scott about its new ultra pure cannabidiol (CBD) capsule – RX7 – which offers high bio-availability. This opens up the opportunity for the company to pursue prescription registration for indications that require a very high dose of CBD, such as anxiety, epilepsy, fibromyalgia and pain conditions. A Phase 1 trial is expected to kick off later this year.